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Lowering intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) is 
still the only evidence-based management strategy.1 
For this purpose, the nonselective β-blocker timolol, 
together with prostaglandin analogs, is licensed as a 
first-line therapy and remains one of the most popu-
lar topical medications in the treatment of glaucoma. 
Key advantages of timolol include its efficacy, low 
cost, extensive familiarity, and superior ocular toler-
ability.2,3 The major drawback with timolol remains 
the potential for cardiovascular systemic adverse 
events due to systemic absorption.4
Timolol is usually formulated as a 0.25% or 0.5% 
solution and is administered twice daily. However, 
more recently, a timolol 0.1% gel-forming carbomer 
(T-Gel 0.1%) has become available that can be 
administered only once a day. The potential advan-
tage of a gel formulation is the extended precorneal 
residence time of the active medication. This may 
offer a larger proportion of timolol being absorbed in 
the eye and an extended duration of action, so that 
Purpose: To investigate the circadian and blood pressure 
(BP) reduction obtained with timolol maleate 0.5% solu-
tion administered twice daily versus timolol 0.1% in gel-
forming carbomer administered in the morning in patients 
with primary open-angle glaucoma (POAG). Methods: 
This investigator-masked, crossover study prospectively 
enrolled naive POAG patients not receiving systemic car-
diovascular medications. Following a baseline evaluation, 
they were randomized to receive a timolol 0.5% solution 
or timolol 0.1% hydrogel for 2 months and then switched 
to the alternative medication for a further 2 months. 
Intraocular pressure (IOP) phasing (sitting Goldmann 
tonometry at 10 am, 2 pm, 6 pm, and 10 pm and supine 
Perkins tonometry at 2 am and 6 am) and ambulatory home 
BP monitoring were measured at baseline and after each 
treatment period. Results: On the basis of a prospective 
sample size estimate, 28 patients were analyzed. Mean 
24-hour IOP decreased from 23.1 ± 0.7 mm Hg at baseline 
to 18.9 ± 0.6 mm Hg after timolol 0.5% and 18.9 ± 0.8 mm 
Hg after timolol 0.1% hydrogel (P < .001); both formula-
tions also significantly decreased diurnal, nocturnal, and 
individual time point IOP in a statistically similar manner. 
Systolic and diastolic BP remained generally unaffected. 
The calculated diastolic ocular perfusion pressure was 
either unaffected or tended to increase with either medica-
tion. Conclusion: Both timolol formulations show similar 
and significant circadian efficacy and have minimal 
effects on BP and calculated diastolic ocular perfusion 
pressure.
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T-Gel 0.1% may be used once daily.5-7 From a clini-
cal viewpoint, the once-daily administration may be 
highly desirable, as evidence shows that patient 
compliance is better with once-a-day dosing 
schemes.8
Due to the prolonged ocular surface bioavailabil-
ity of active ingredients with gel formulations, the 
amount of medication available for systemic absorp-
tion through the nasolacrimal apparatus is decreased, 
and the likelihood of systemic adverse events may 
be minimized. This potential advantage may be of 
clinical relevance, as systemic adverse events often 
pose a concern in patients treated with topical 
β-blockers. For instance, it has been found that topi-
cal β-blockers affect systemic hemodynamic param-
eters such as systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and heart rate.9-11 Nonetheless, 
the effect of different timolol formulations on circa-
dian IOP and blood pressure has not been adequately 
described.8,12,13
Although it has been shown that both the timolol 
0.5% solution and T-Gel 0.1% have comparable day-
time efficacy,5-7 there is no published evidence on the 
circadian IOP efficacy and the effect upon 24-hour 
blood pressure of these 2 different formulations.
In this current study, we evaluated a T-Gel 0.1% 
formulation used once daily in the morning in 
newly diagnosed and previously untreated POAG 
patients and compared its effect on 24-hour IOP and 
blood pressure reduction with that of the commonly 
used timolol maleate 0.5% solution used twice 
daily.
MeThOdS
This prospective, randomized, investigator-masked, 
crossover study complied with the tenets of the 
Declaration of Helsinki, and its research protocol 
was approved by the Institutional Review Board of 
the Medical School of Aristotle University of 
Thessaloniki. Written informed consent was 
obtained from all patients before they were enrolled.
All newly diagnosed and previously untreated 
patients with mild-to-moderate POAG aged >45 
years were offered the opportunity to participate in 
this study. The European Glaucoma Society criteria 
for the diagnosis of POAG were adhered to, and 
patients were enrolled if their morning (10:00 ± 1 
hour) untreated IOP was higher than 25 mm Hg.
Exclusion criteria for ophthalmic conditions were 
any type of glaucoma other than POAG, corneal or 
other anatomical conditions making applanation 
tonometry unreliable, central corneal thickness ≤500 
μm or ≥600 μm, previous laser treatment or any ocu-
lar surgery, best corrected visual acuity (BCVA) less 
than Snellen 0.4, cup-to-disc ratio ≥0.8, mean devia-
tion worse than –15 dB in Humphrey 24-2 SITA 
standard perimetry, or the possibility of visual func-
tion deterioration and optic nerve damage as a result 
of study procedures according to the investigator’s 
judgment. Exclusion criteria related to systemic con-
ditions were inability to understand the study proce-
dures and give informed consent and contraindications 
to β-blocker treatment (obstructive pulmonary dis-
ease, second- or third-degree atrioventricular block, 
bradycardia, and severe heart failure). Additionally, 
patients were excluded if they had a history of cardio-
vascular disease (eg, heart disease, arrhythmia, or 
arterial hypertension) and concomitant systemic 
treatment that could modify blood pressure (BP), 
such as β-blockers, calcium channel blockers, angio-
tensin-converting enzyme inhibitors, or diuretics.
Assessments
During an initial eligibility visit, all study patients 
underwent a detailed ophthalmic examination. 
Enrolled participants were admitted to the hospital 
for an untreated baseline 24-hour IOP assessment at 
habitual position, with Goldmann tonometry per-
formed at 10:00, 14:00, 18:00, and 22:00 (± 1 hour) 
and Perkins tonometry with the patient supine in 
bed at 02:00 and 06:00 (± 1 hour).
Ambulatory BP was recorded using an automated 
portable device (TM-2430, A&D Co, Saitama, Japan), 
which indirectly determines BP by means of oscillo-
metrically measuring the vibratory signals associated 
with blood flow in the brachial artery, and satisfies 
the SBP and DBP accuracy levels recommended by 
the British Hypertension Society and the Association 
for the Advancement of Medical Instrumentation.14 
An appropriately sized cuff was placed on the par-
ticipant’s nondominant arm, and BP was measured 
automatically every 15 minutes between 08:00 and 
22:00 and every 30 minutes between 22:00 and 08:00. 
If a reading was not obtained properly, the device was 
programmed to repeat it. The BP values recorded 
throughout the 24-hour period were subsequently 
recovered from the recording chip and stored in a 
personal computer.
The hospital IOP measurements and home BP 
monitoring were made on consecutive days in order 
to prevent any influence of the former on the latter.15 
The first IOP measurements were made every 4 
hours from 10 am on day 1 to 6 am on day 2, after 
which the patients were fitted with the dynamic BP 
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measuring device and were discharged. The device 
was kept in place for 24 hours (until 7 am on day 3), 
during which the patients were asked to follow their 
usual routine as much as possible. Subsequently, the 
patients were randomly assigned to 2 months’ topi-
cal treatment with a timolol 0.5% solution (Timoptol 
0.5%, Merck Sharp & Dohme, Rome, Italy) adminis-
tered twice daily (08:00 and 20:00) or Timogel 0.1% 
(Laboratoires THEA SA, Clermont-Ferrand, France) 
once in the morning (08:00). At the end of this 
period, the patients were again admitted to the clinic 
to repeat the 24-hour IOP and ambulatory BP assess-
ments in the same way as at baseline. The morning 
after the assessment, the patients were switched to 
the opposite medication for a period of another 2 
months, after which they were once again admitted 
to the clinic to repeat the 24-hour IOP and ambula-
tory BP evaluation.
Patients were instructed to instill the medication by 
the study nurse (one single drop into the lower con-
junctival sac, and nasolacrimal occlusion for at least 1 
minute). Patients were asked to give back the bottles 
of study medications every 3 weeks, and the use of 
T-Gel 0.1% and timolol 0.5% was verified by the 
study nurse. In all cases, utilization of medications 
appeared to be in keeping with the study duration. A 
detailed clinical examination was performed during 
all of the periods of hospitalization, and investigator-
observed adverse events and patient-reported symp-
toms or complaints concerning the medication were 
recorded. The IOP was always measured by 2 well-
trained investigators who were unaware of the treat-
ment regimen. The same calibrated Goldmann and 
Perkins tonometers were used throughout the study.
endpoints
The primary study endpoints were mean nocturnal 
and 24-hour IOP. Nocturnal IOP was calculated at 
baseline and at the end of each treatment period as 
the mean of the assessments at 2 am and 6 am. The 
secondary endpoints were IOP at each time point, 
24-hour SBP, DBP, and diastolic ocular perfusion 
pressure (DOPP, calculated at each time point as the 
difference between DBP and IOP). Study drug–
related adverse events were also assessed.
Statistical Methods
One eye per patient was analyzed (if both eyes 
fulfilled the eligibility criteria, the eye with the higher 
IOP was used). An intent-to-treat approach was 
used, and in case of missing data, the last observation 
available was carried forward. The safety population 
included all patients who received at least one treat-
ment. Patients were assigned to treatment groups 
based on what they actually received. In each patient, 
for each endpoint, the difference of pressure values at 
the end of each treatment period versus baseline was 
calculated and compared by means of a paired t test. 
Incidence of adverse events was analyzed by means 
of the McNemar test.
The sample size estimate was based on the differ-
ence from baseline of IOP after 2 months of treat-
ment with the timolol 0.5% solution or T-Gel 0.1%, 
with a mean difference of ≥1 mm Hg (and a standard 
difference of 1.5 mm Hg) being considered relevant. 
At a significance level of .05 for a 2-sided test and a 
power of .80, it was calculated that 28 patients were 
required.
Data are presented as mean (standard deviation 
[SD]) or absolute frequency and percentage. Statistical 
significance was set at .05. No adjustment for multi-
ple testing was performed. Therefore, all the analyses 
other than that of the primary endpoint are to be con-
sidered as hypothesis generating. The analyses were 
made using SAS software (Statistical Analysis System, 
version 9.1, SAS Institute Inc, Cary, North Carolina).
ReSuLTS
Twenty-eight POAG patients completed the study 
(Table I). There were no serious systemic adverse 
effects; all of the reported adverse events were local: 
timolol 0.5%– and T-Gel 0.1%–related adverse 
events (the number of patients reporting or being 
observed having an adverse event, McNemar test): 
ocular foreign body sensation: 9 (32%) versus 7 
(25%), P = .558; conjunctival hyperemia: 11 (39%) 
versus 8 (28%), P = .401; ocular itching: 6 (21%) 
versus 3 (10%), P = .279; ocular stinging: 6 (21%) 
versus 5 (17%), P = .739; punctate corneal epitheli-
opathy: 2 (7%) versus 1 (3%), P = .556. None of the 
patients showed a decrease in BCVA or any signs of 
glaucoma progression during the study.
Table I Patient Demographics
Patients, n 28
White, n (%) 28 (100)
Age, mean (SD), minimum-maximum, 
y
62 (10), 45-78
Male, n (%) 15 (53)
Central corneal thickness, mean (SD), 
minimum-maximum, μm
538 (22), 507-579
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The trends over time at baseline and after 2 
months of treatment with either T-Gel 0.1% or timo-
lol 0.5% of IOP are shown in Figures 1 and 2, while 
the nocturnal IOP, the IOP at each time point, as well 
as 24-hour IOP, BP, and calculated DOPP values are 
described in Table II.
Although each medication significantly reduced 
IOP with reference to baseline values, the compari-
son of these decreases between drugs did not show 
any statistically significant difference for nocturnal 
IOP, 24-hour IOP, and for each single IOP time point.
dISCuSSIOn
We examined the 24-hour ocular hypotensive effects 
and tolerability of a timolol 0.5% solution adminis-
tered twice daily and T-Gel 0.1% administered in 
the morning in naive POAG patients not receiving 
systemic cardiovascular medication. We also inves-
tigated the effects of the formulations on SBP and 
DBP and calculated DOPP throughout the 24-hour 
cycle. The study was undertaken because of concern 
that topical β-blockers may be less efficacious dur-
ing the night and may also decrease ocular perfusion 
due to alterations in systemic circulatory parame-
ters.9-11,16-19 Hayreh et al have found that patients 
with normal tension glaucoma treated with timolol 
have lower nocturnal BP and heart rate,9 and Netland 
et al have reported that nocturnal heart rate dipping 
(<60 beats/minute) is more frequent in timolol-
treated patients.10 Liu et al have found that patients 
on β-blockers do not experience any nocturnal 
reduction in supine IOP.16
Our findings show that the 2 timolol formulations 
are equally effective in reducing the IOP of POAG 
patients throughout the 24-hour cycle. It is worth not-
ing that the nocturnal IOP measurements were made 
using a Perkins tonometer with the patients lying 
supine, and so our results differ from those of Liu 
et al, who did not detect any ocular hypotensive effect 
in POAG patients receiving 0.5% gel-forming timolol 
once daily in the morning.16 It is also worth noting that 
our patients showed an average difference of 1.3 mm 
Hg between sitting diurnal and supine nocturnal IOP 
at baseline, whereas the difference in the patients 
studied by Liu et al was 2.7 mm Hg.16 Although we 
used Goldmann tonometry for the diurnal measure-
ments and Perkins tonometry for the nocturnal meas-
urements, and Liu et al used a pneumatonometer for 
all of the measurements, differences in the study sam-
ples might account for these discrepancies.16
Our efficacy data are in line with those of oth-
ers11,18,20 and with those of a recently published 
meta-analysis by Lee et al.21 In particular, they found 
that topical timolol treatment is effective throughout 
the 24 hours, and we found that both timolol formu-
lations were equally efficacious in lowering mean 
24-hour, diurnal, nocturnal, and individual time 
point IOP.21
The potential effects of topical β-blockers on BP 
described in other studies9,11,17-19 were not observed 
during our study. These findings are in line with 
those of other studies and the recent meta-analysis 
by Lee et al.21,22
Figure 1. Twenty-four–hour, diurnal, and nocturnal mean 
intraocular pressure (IOP) curves for the patients at baseline and 
after treatment with timolol 0.5% solution and T-gel 0.1%. The 
error bars represent one standard deviation.
Figure 2. Intraocular pressure (IOP) curves at each time point at 
baseline and after treatment with timolol 0.5% solution and 
T-gel 0.1%. The error bars represent one standard deviation.
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Epidemiological studies have shown that low cal-
culated DOPP is associated with an increased preva-
lence and incidence of POAG.23-26 We found that 
both timolol formulations tended to improve diurnal 
calculated DOPP, although the improvement did not 
reach statistical significance.
As we did not examine the long-term prognosis of 
patients treated with the 2 formulations, no conclu-
sion can be drawn concerning their usefulness in a 
clinical setting. Similarly, the real advantage of 
once-daily T-Gel 0.1% instillation over the twice-
daily administration of the conventional timolol 
0.5% solution remains to be determined. Some other 
limitations of our study also need to be borne in 
mind. Specifically, we did not assess patient compli-
ance, and our study sample may have been inade-
quate to detect differences in adverse events. 
Additionally, although both Goldmann and Perkins 
tonometry have been studied in detail and are 
widely used for similar investigations,11,27,28 our find-
ings may not be perfectly comparable with those of 
investigators who have used different tonometers.16
In conclusion, the T-Gel 0.1% formulation admin-
istered once daily is as well tolerated and has at least 
the same 24-hour efficacy as the 0.5% timolol solu-
tion administered twice daily. Furthermore, both 
formulations have minimal effects on BP and calcu-
lated DOPP throughout the 24-hour cycle.
Financial disclosure: None declared.
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